Egypt’s Eva Pharma has begun producing remdesivir and favipiravir to treat patients with COVID-19, as reported in the Financial Post.
Earlier this month, Eva Pharma received a licence from Gilead Sciences to produce remdesivir in Egypt and distribute it to 127 countries.
The drugmaker will initially make 500,000 doses a month to be sold at a price less than 2000 Egyptian pounds each, said general manager Amgad Talaat, adding that they’ve already started delivering the medicine to hospitals.
Talaat said that Eva Pharma has also started producing 1 million favipiravir tablets a month, which will be on the market within two to three weeks.
The company hopes to sell any excess doses to other Middle Eastern and African countries, said Talaat.
To read more NewsPoints articles, click here.